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1    Introduction
Melatonin is a natural hormone produced by the pineal 
gland in the brain [1, 2]. In humans, it regulates the body’s 
circadian sleep-wake cycle [3] and is used as sleep-aid [4, 
5], anti-oxidant [6], and over-the-counter dietary supple-
ments based on melatonin have been available for many 
years in the US. Moreover studies suggest that the mela-
tonin hormone is also an effective cancer inhibitor [7, 8], 
can be beneficial in treating neurodegenerative diseases 
[9], and is useful to fight depression and anxiety [10]. The 
first commercially available melatonin was produced via 
extraction of pineal glands of animals [1]. However, one 
of the biggest drawbacks of the extraction process is 
the danger of viral contamination of the animal tissue. 
Therefore, melatonin is typically chemically synthesized, 
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requiring toxic solvents and catalysts [11, 12], albeit that 
all of these solvents and chemical intermediates are abun-
dantly available. 
This has created a compelling case for a biological pro-
duction process, which could potentially be the dominant 
production process for melatonin in the future. In mam-
mals, melatonin is primarily synthesized in the pineal 
gland in a four-step pathway using L-tryptophan as a pre-
cursor, which is a downstream metabolite of the intrinsic 
shikimate pathway [13, 14]. For recombinant melatonin 
production, we chose budding yeast Saccharomyces 
cerevisiae as the host, since the product is intended for 
food supplement and medical applications. To the best 
of our knowledge, this is the first report on heterologous 
production of melatonin from glucose. 
2    Materials and methods
2.1    Strains and chemicals
Escherichia coli DH5a was used for cloning, S. cerevisiae 
CEN.PK strains were obtained from Peter Kötter (Johan 
Wolfgang Goethe-University Frankfurt, Germany). All oli-
gos are listed in Supporting information, Table S1, DNA 
BioBricks are listed in Supporting information, Table S2, 
plasmids are listed in Supporting information, Table S3, 
and yeast strains are listed in Supporting information, 
Table  S4. EasyClone plasmids used in this study are 
described in Jensen et al. [15]. All chemicals were from 
Sigma-Aldrich, except nourseothricin (Werner BioAgents).
2.2    Media
E. coli was cultivated at 37°C in LB medium. S. cerevisiae 
was cultivated at 30°C on synthetic complete medium 
or drop-out media prepared with pre-mixed drop-out 
powders from Sigma-Aldrich. Mineral medium was pre-
pared as described previously [15]. Synthetic fed-batch 
(FIT) medium M-Sc.syn-1000 was prepared according 
to manufacturer’s instructions (M2P labs GmbH). FIT 
medium was supplemented with the supplied vitamins 
solution (final concentration 1% v/v) and the enzyme mix 
(final concentration 0.5% v/v) immediately prior to use.
2.3    Cultivation and analysis
For cultivating yeast strains, single colonies originating 
from independent transformants were inoculated from 
a pre-culture grown in selective minimal medium into 
500  µL FIT medium or mineral medium supplemented 
with 20 g L–1 glucose in a 96-deep well microtiter plate 
with air-penetrable lid (EnzyScreen, NL). The microtiter 
plates were incubated at 30°C with 300  rpm agitation 
at 5 cm orbit cast, cells were allowed to grow for 72 h. 
For some experiments, the mineral medium was supple-
mented with 500 mg L–1 methionine or 500 mg L–1 tryp-
tophan. For harvesting, an equal amount of 96% ethanol 
was added to the supernatant or the total cell suspension, 
mixed thoroughly, the ethanol-extracted culture filtered 
(0.22 µm), and subjected to LC-ESI-MS analysis (details 
of the LC-ESI-MS method are found in the Supporting 
information).
2.4    Statistics
For statistical evaluations of the changes in production 
levels, data were analyzed for significant differences by 
unpaired two-tailed t-tests using GraphPad Prism version 
6.00 for Windows (GraphPad Software, La Jolla, California, 
USA).
3    Results and discussion
3.1     Pathway engineering for sugar-based 
recombinant biosynthesis of melatonin in yeast
In this study, a de novo pathway for melatonin produc-
tion was established in S. cerevisiae by the extension 
of the shikimate synthesis pathway. The biosynthesis 
pathway is described in Fig.  1, the connections to the 
intrinsic yeast metabolism are depicted in Supporting 
information, Fig. S1. The amino acid L-tryptophan is the 
intrinsic precursor, which is converted to 5-hydroxy-L-
tryptophan (5-HTP) by tryptophan hydroxylase (TPH) [16]. 
TPH requires both oxygen and the cofactor tetrahydrop-
terin (THB, also known as BH4). 5-HTP is decarboxyl-
ated to serotonin by 5-hydroxy-L-tryptophan decarbox-
ylase (DDC) [17], and serotonin is acetylated to N-ace-
tylserotonin by serotonin N-acetyltransferase (AANAT), 
requiring acetyl-coenzyme A (acetyl-CoA) [18]. Finally, 
N-acetylserotonin  O-methyltransferase (ASMT) methyl-
ates N-acetylserotonin to the final product melatonin 
[19]. During this last step, the conversion to melatonin 
is accompanied by the co-conversion of S-adenosyl-L-
methionine (SAM) to S-adenosyl-L-homocysteine (SAH). 
SAH can then be recycled back to SAM via the S-ade-
nosyl-L-methionine cycle (SAM cycle) (Fig. 1). The SAM 
cycle is native and constitutively expressed in budding 
yeast [20]. 
In order to establish a functional heterologous pathway 
that produces melatonin de novo, we ventured to con-
struct a melatonin producing strain that utilizes endoge-
nous L-tryptophan generated from glucose. Since we had 
concerns about the stability of 5-HTP observed in initial 
experiments (data not shown), we directly constructed 
production strains that contained the entire pathway from 
L-tryptophan to melatonin. Additionally, we introduced 
the BH4 biosynthesis and regeneration pathways in order 
to avoid the need to add chemically synthesized BH4, 
which is the cofactor for TPH. The pathway for BH4 bio-
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synthesis comprises a GTP cyclohydrolase I (GCH1, FOL2 
in S. cerevisiae), a 6-pyruvoyl-tetrahydropterin synthase 
(PTS) and a sepiapterin reductase (SPR), and converts 
GTP into BH4 [21, 22] (Fig. 1). Conveniently, the enzyme 
GCH1/Fol2 is natively present in wild-type S. cerevisiae, 
whereas heterologous PTS and SPR were introduced to 
enable BH4 production in budding yeast. The enzymes 
4a-hydroxytetrahydrobiopterin dehydratase (PCBD1) and 
6-pyruvoyl-tetrahydropterin synthase (DHPR) complete 
the BH4 regeneration pathway. 
For all pathway genes, a variety of homologues were 
chosen based on functional conservation to the mamma-
lian melatonin pathway enzymes, and the most promising 
candidates from initial functionality analysis for single 
substrate conversion in E. coli (data not shown) were 
chosen for strain engineering in yeast. We generated 
recombinant strains overexpressing Rattus norvegicus 
RnPTS, R. norvegicus RnSPR, one of two homologues of 
PCBD1 (Lactobacillus ruminis LrPCBD1 or Pseudomonas 
aeruginosa PaPCBD1), and one of two homologues of 
DHPR (Homo sapiens HsDHPR or R. norvegicus RnDHPR), 
thereby providing the BH4 biosynthesis and regeneration 
capability. Genes encoding either a double truncated 
version of H. sapiens HsTPH2 (Q8IWU9) [23], or Schis-
tosoma mansoni SmTPH [24] were introduced to enable 
the conversion of L-tryptophan to 5-HTP. Here, truncated 
HsTPH146-460 lacking both the N- and the C-terminus 
regulatory regions was used in order to increase heterolo-
gous expression and enhance protein stability [25]. Sub-
sequently, the downstream pathway genes for producing 
melatonin from 5-HTP were integrated, i.e. H. sapiens 
HsDDC, Bos taurus BtAANAT, and H. sapiens HsASMT 
(Fig. 2A). The derived strains were analyzed after small-
scale cultivation in mineral medium with glucose as 
sole carbon source. The cells produced substantially 
0.3–0.8 mg L–1 of melatonin, 0.0–2.4 mg L–1 of serotonin, 
and 4.0–9.1  mg  L–1 of N-acetylserotonin (Fig.  2B; Sup-
porting information, Table S5). None of these three com-
pounds were detected in the reference non-engineered 
yeast strain. Having confirmed the functionality of the 
de novo biosynthetic pathway, we ventured to improve 
the metabolic flux towards melatonin by optimizing gene 
expression. 
3.2     Improved production of melatonin by higher 
expression of two flux controlling enzymes
Next we investigated whether improved overexpression 
of TPH is beneficial in order to boost the flux towards 
melatonin. To analyze this, we used an integrative vector 
that causes multi-copy integration into Ty retrotranspo-
son sites. Integration of the rate-limiting enzyme into 
yeast Ty sites has previously been shown to be beneficial 
for production of 3-hydroxypropionic acid [26]. Yeast 
retrotransposons are a family of transposable elements 
that are dispersed throughout the eukaryotic genome in 
high numbers [27, 28], and therefore represent attractive 
target sites for multi-copy integration. Accordingly, we 
introduced the genes coding SmTPH and HsTPH2146-460 
under the control of the strong PPGK1 promoter in multi-
copy via expression vectors targeting yeast retrotrans-
poson Ty2 sites. We investigated TPH copy number and 
mRNA expression levels by QPCR and RT-QPCR, and 
could confirm that there are more copies integrated, and 
Figure 1. Overview of heterologous mela-
tonin biosynthesis in Saccharomyces cerevisiae. 
Melatonin is synthesized from L-tryptophan 
by four enzymatic steps and with the BH4 
biosynthesis and regeneration pathways to 
supply the BH4 cofactor. Enzymatic reactions 
are indicated by arrows, native reactions are 
in grey and recombinant ones are in red. 
The enzymes overexpressed in this study are 
marked in dark grey with white letters, native 
enzymes are marked in light grey with black 
letters.
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most importantly that expression levels are substantially 
increased compared to single integration (Supporting 
information, Fig. S3, Table S6). The derived strains were 
tested for melatonin production after small-scale cultiva-
tion in mineral medium. The cells with HsTPH2146-460 
overexpressed from Ty2 sites did not show any significant 
improvement of production, we measured melatonin at 
0.4–0.9 mg L–1, and N-acetylserotonin at 4.9–7.2 mg L–1 
(Fig. 2B; Supporting information, Table S5). Interestingly, 
we observed a clear effect of choice of BH4 recycling 
pathway on production performance. Strains carrying 
PaPCBD1/RnDHPR produced five-fold more melatonin 
than those carrying the LrPCBD1/HsDHPR homologues. 
Importantly, we achieved significantly higher titers 
of melatonin at 1.9 mg L–1, and highly increased titer of 
N-acetylserotonin at 16.7  mg  L–1 when overexpressing 
SmTPH from Ty2 sites (Ty2::SmTPH) in the presence of 
PaPCBD1/RnDHPR (Fig. 2B–D; and Supporting informa-
tion, Table  S5), and could obtain high clonal reproduc-
ibility with regards to metabolite production (Supporting 
information, Fig.  S2). This represents an approximate 
two-fold increase in melatonin production in comparison 
to HsTPH2146-460, indicating that S. mansoni TPH clearly 
outperforms H. sapiens TPH. Regarding the expression 
of SmTPH from Ty2 sites, we tested three independent 
clones and observed variable copy numbers of 2, 3 and 
11. However, RT-QPCR revealed that mRNA expression 
levels were increased to similar high levels of 13.6 ± 1.6 
relative to S. cerevisiae ScACT1 (Supporting information, 
Fig. S3, Table S6). Interestingly, the choice of BH4 recy-
Figure 2. Metabolite production in yeast strains expressing the melatonin biosynthesis pathway from glucose. (A) Overview of the enzymatic steps for 
the conversion of L-tryptophan into melatonin. (B) Conversion of glucose to melatonin and intermediates by recombinant S. cerevisiae strains. Ethanol-
extracted concentrations of indicated metabolites in the fermentation broth of cells cultivated on mineral medium as measured by LC/ESI-MS. The strains 
express RnPTS, RnSPR, HsDDC, BtAANAT, HsASMT, and different combinations of TPH, PCBD and DHPR genes. The numbers are average values with 
error bars representing standard deviations for at least three individual strain isolates of one cultivation. “+” denotes that a single copy was integrated into 
the genome, “+++” denotes that multiple copies of the gene were integrated into the genome. (C) LC analysis of the standard (left), and of the bioconver-
sion products of the representative clone 7 of strain SCE-iL3-HM-43 (Ty2:: SmTPH PaPCBD1 RnDHPR RnPTS RnSPR HsDDC BtAANAT HsASMT) from 
glucose (right). Top: complete chromatogram. Compound 1 (serotonin), compound 2 (N-acetylserotonin), and compound 3 (melatonin) have a retention 
time of 0.6, 1.7 and 2.2 min, respectively. Asterix indicate the main peak in the respective chromatogram. (D) LC-ESI-MS analysis of the standard and of 
metabolites from the production clone described in panel C in the positive mode: exact mass of compound 1 [M + H]+ [m/z] (160.076), compound 2  
[M + H]+ [m/z] (219.113), compound 3 [M + H]+ [m/z] (233.128).
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cling pathway had an even more pronounced impact on 
melatonin production with SmTPH overexpressed from 
Ty2 sites, as we observed an approximate 64-fold increase 
in melatonin production when PaPCBD1/RnDHPR were 
integrated compared to LrPCBD1/HsDHPR (Fig. 2B; Sup-
porting information, Table S5). We can therefore conclude 
that the BH4 recycling pathway with PaPCBD1 and 
RnDHPR is beneficial for melatonin production. In order 
to verify that the BH4 recycling pathway is essential for 
melatonin production, we constructed strains that con-
tain the complete pathway including the TPH variants 
in single or multi-copy, but lack PTS, SPR, PCBD1 and 
DHPR. Indeed, we did not observe any production in 
these strains (Fig.  3C). For future improvement, the 
investigation of other variants of BH4 cofactor regenera-
tion enzymes, optimizing protein expression, or different 
promoter choice might be of interest.
Interestingly, we consistently observed about 10-fold 
elevated levels of N-acetylserotonin compared to mela-
tonin in all melatonin-producing strains (Fig.  2B; Sup-
Figure 3. Optimization of metabolite production in yeast strains expressing the melatonin biosynthesis pathway. (A) Effect of introducing the episomal 
HsASMT plasmid on melatonin production. Strains SCE-iL3-HM-44 and SCE-iL3-HM-45 (Ty2:: SmTPH PaPCBD1 RnDHPR RnPTS RnSPR HsDDC 
BtAANAT HsASMT, transformed with pCfB3337 [pESC-HsASMT, 2µ]), which are derived from two independent clones of SCE-iL3-HM-43, were cultured 
in mineral medium, the supernatant extracted with ethanol, and analyzed by LC-ESI-MS. Measured concentrations were normalized to metabolites pro-
duced by  SCE-iL3-HM-43, and error bars representing standard deviations calculated from biological triplicates of one cultivation. Statistical significance of 
changes in production is indicated as ns (not significant) or asterix (*, significant). (B) Production titers of the best producing melatonin strain in different 
cultivation media. The non-producing strain CEN.PK 113-7D and the best producing strain SCE-iL3-HM-43 that carries genes for overexpressing RnPTS, 
RnSPR, PaPCBD1, RnDHPR, HsDDC, BtAANAT, HsASMT, and Ty2:: SmTPH were cultivated in mineral medium (MM) or in FIT medium, subjected to 
ethanol extraction of the total cell suspension, and analyzed by LC-ESI-MS. The average and error bars representing standard deviations were calculated 
from biological duplicates of one cultivation. (C) Production titers of melatonin producing strains with additional genomic modifications. Strains SCE-
iL3-HM-48, 49, 50 and 51 carry genes for overexpressing HsDDC, BtAANAT, HsASMT, and either HsTPH146-460 or SmTPH in single copy (+) or at Ty2 
sites (+++), but lack all four BH4 pathway genes. Strains SCE-iL3-HM-53, 57, 60, 63 and 66 are offspring of SCE-iL3-HM-43 clone 61, and carry genes for 
overexpressing RnPTS, RnSPR, PaPCBD1, RnDHPR, HsDDC, BtAANAT, HsASMT, and Ty2:: SmTPH. In addition, either ScARO9 is deleted, or one of the 
following genes is overexpressed: SeACS, ScALD6, ScSAM2, or ScERC1. Cells were cultured in FIT media, total cell suspension extracted with ethanol, and 
metabolites measured by LC-ESI-MS. Error bars represent standard deviations, and were calculated based on biological triplicates of one cultivation.
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porting information, Table  S5). We therefore analyzed 
whether we could enhance conversion by increasing 
the expression of HsASMT. To test this hypothesis, we 
introduced an episomal high-copy (2µ) plasmid bearing 
HsASMT into two independent clones of the melatonin 
production strain that overexpress SmTPH from Ty2 sites. 
We observed a 1.5-fold decrease of serotonin and a 1.2-
fold decrease of N-acetylserotonin. However, both were 
not significantly different to the control. Importantly, we 
found a significant 1.8-fold increase of melatonin when 
HsASMT was overexpressed from the high-copy plasmid 
(p = 0.0202) (Fig. 3A), supporting the notion that the path-
way flux is pushed towards product formation. Future 
research might further focus on balancing other enzy-
matic steps in this heterologous pathway. In addition, 
we investigated whether we could improve conversion of 
N-acetylserotonin by enriching S-adenosyl-L-methionine 
(SAM) in the cell in order to shift the ASMT reaction 
equilibrium towards the product. We cultured biologi-
cal triplicates of all eight melatonin-producing strains 
in media supplemented with 500  mg  L–1 methionine, 
the precursor of SAM. However, we did not observe any 
significant improvement of production (data not shown). 
This might be due to the presence of feedback inhibiting 
or other regulatory processes in the cell. As an alternative, 
we conducted genomic engineering approaches in order 
to increase SAM supply. In S. cerevisiae, there are two 
isogenes, SAM1 and SAM2, encoding SAM synthetase. 
ScSAM2 was chosen for overexpression since it has been 
shown that the expression of the ScSAM2 gene increases 
during cell growth, and overrides the repressive effect 
of SAM [29]. We also overexpressed the S. cerevisiae 
ethionine resistance conferring gene ScERC1, since it 
was reported that overexpressing ScERC1 improves the 
accumulation of SAM in yeast [30]. We introduced these 
genes into the best producing strain SCE-iL3-HM-43 
(carrying RnPTS, RnSPR, PaPCBD1, RnDHPR, HsDDC, 
BtAANAT, HsASMT and Ty2::SmTPH), cultivated inde-
pendent clones in mineral or FIT medium, and performed 
ethanol extraction of the total cell suspension, as opposed 
to the extraction of supernatant in previous experiments. 
This different extraction method of the parent strain cul-
tured in mineral medium resulted in increased titers of the 
intermediate metabolites serotonin at 65.9 ± 1.0 mg L–1, 
and N-acetylserotonin at 22.1  ±  0.2  mg  L–1. However, 
melatonin production was not increased and remained 
at 1.4  ±  0.3  mg L–1 (Fig.  3B; Supporting information, 
Table S7). Strikingly, we achieved highly decreased titers 
of serotonin at 2.0 ± 0.0 mg L–1, strongly increased titers 
of N-acetylserotonin at 43.3 ± 7.1 mg L–1, and significantly 
higher titers of melatonin at 13.2 ± 2.1 mg L–1 in the parent 
strain when cultured in FIT medium, which represents a 
strong shift toward product formation (Fig. 3B; Support-
ing information, Table  S7). Meanwhile, overexpression 
of ScSAM2 or ScERC1 was not beneficial for melatonin 
production, as we observed no significant changes com-
pared to parent strain (Fig. 3C; Supporting information, 
Table S8). Supplementing these strains with methionine 
decreased metabolite production even more (data not 
shown). We conclude that improving melatonin titers by 
metabolic engineering of the SAM cofactor supply is not 
as straightforward as anticipated. This is however very 
worthwhile investigating in the future, since the metabo-
lite profile in FIT medium shows high accumulation 
of N-acetylserotonin, and therefore the ASMT reaction 
seems to be the major bottleneck.
3.3     Further strategies for improving production 
titers of melatonin
Furthermore, we investigated whether increased precur-
sor L-tryptophan availability is beneficial for melatonin 
production. There are a number of tryptophan overpro-
ducers available in E. coli [31] or cereal crops [32]. One 
might consider investigating these platform strains as 
alternative chassis for melatonin production in future 
research. In any case, aromatic amino acid pools are very 
tightly regulated in yeast S. cerevisiae, and to the best 
of our knowledge, there is no yeast tryptophan overpro-
ducer available yet. We therefore analyzed melatonin 
production in media supplemented with tryptophan. 
However, this approach did not lead to any measurable 
improvement (data not shown). We then ventured to 
analyze whether the deletion of the S. cerevisiae ScARO9 
gene might be beneficial for melatonin production, since 
we observed reduced degradation of 5-HTP in initial 
single enzymatic conversion studies [33]. Aro9 is an 
aromatic aminotransferase II and catalyzes the first step 
of tryptophan, phenylalanine, and tyrosine catabolism 
[34]. We deleted ScARO9 in the best producing strain 
SCE-iL3-HM-43, cultivated the clones in FIT or mineral 
medium, and measured production. We did not observe 
any significant change in melatonin levels (Fig. 3C; Sup-
porting information, Table S8). Possibly, the DDC reaction 
is efficient enough to compete with the 5-HTP degrada-
tion pathways and redirects the flux towards serotonin 
production. Therefore, deleting ScARO9 has no effect on 
overall production.
Alternatively, increasing acetyl-CoA levels might 
improve titers of melatonin, since it is consumed during 
the acetylation of serotonin by AANAT [18]. Therefore, a 
higher acetyl-CoA/CoA ratio could favor product genera-
tion. Feeding carbon sources such as glucose improves 
acetyl-CoA availability in the cell, but there are many 
competing metabolic pathways consuming acetyl-CoA. 
Limiting oxygen can inhibit a subset of these competing 
pathways and thereby increase acetyl-CoA supply [35]. 
However, we did not further investigate this strategy, 
since the upstream conversion of L-tryptophan to 5-HTP 
requires oxygen, and is probably not functional under 
oxygen limiting conditions. Therefore, we ventured to 
improve the supply of acetyl-CoA, by overexpressing 
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the cytosolic acetaldehyde dehydrogenase ScALD6 of S. 
cerevisiae or acetyl-CoA synthase SeACS of Salmonella 
enterica [36]. We introduced these modifications into the 
best producer SCE-iL3-HM-43, cultivated the clones in 
FIT or mineral medium, and observed a minor increase 
in melatonin production by 5% (SeACS) or 10% (ScALD6) 
(Fig.  3C; Supporting information, Table  S8). However, 
these changes are not significant. Nevertheless, we were 
confident to have obtained an improved best producing 
strain overexpressing ScALD6 (SCE-iL3-HM-60), since 
it produces melatonin with very low clonal variation at 
14.5 ± 0.6 mg L–1. Lastly, increasing NADH and NADPH 
pools might be of interest in future investigations for 
improving titers of melatonin, since they are consumed 
during the acetylation step by AANAT [18] or during the 
BH4 biosynthesis and regeneration pathways, respec-
tively.
4    Concluding remarks
In contrast to biological tissue extraction and chemical 
synthesis, production of active biological ingredients 
using metabolically engineered microorganisms ferment-
ing renewable feedstocks is an attractive process. In this 
study, we have assembled a recombinant melatonin path-
way in S. cerevisiae and demonstrated de novo produc-
tion of melatonin and its related compounds from glucose 
for the first time. We have identified the ASMT reaction as 
the major bottleneck, and gene expression optimization 
was proven to be beneficial. Overall, our initial exploration 
is providing a promising basis for future improvements 
and investigations. 
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